Use of biologic agents and methotrexate improves renal manifestation and outcome in patients with rheumatoid arthritis: a retrospective analysis

被引:10
作者
Sawamura, Masato [1 ,2 ,7 ]
Sawa, Naoki [1 ,2 ,4 ]
Yamanouchi, Masayuki [1 ,2 ]
Ikuma, Daisuke [1 ,2 ]
Sekine, Akinari [1 ,2 ]
Mizuno, Hiroki [1 ,2 ]
Kawada, Masahiro [1 ,2 ]
Hiramatsu, Rikako [1 ,2 ]
Hayami, Noriko [1 ,2 ]
Hasegawa, Eiko [1 ,2 ]
Suwabe, Tatsuya [1 ,2 ]
Hoshino, Junichi [1 ,2 ,4 ]
Kono, Kei [3 ]
Kinowaki, Keiichi [3 ]
Ohashi, Kenichi [3 ,5 ]
Yamaguchi, Yutaka [6 ]
Ubara, Yoshifumi [1 ,2 ,4 ]
机构
[1] Toranomon Gen Hosp, Nephrol Ctr, Tokyo, Japan
[2] Toranomon Gen Hosp, Dept Rheumatol, Tokyo, Japan
[3] Toranomon Gen Hosp, Dept Pathol, Tokyo, Japan
[4] Toranomon Gen Hosp, Okinaka Mem Inst Med Res, Tokyo, Japan
[5] Tokyo Med & Dent Univ, Dept Human Pathol, Tokyo, Japan
[6] Yamaguchis Pathol Lab, Chiba, Japan
[7] Toranomon Gen Hosp, Nephrol Ctr, Takatsu Ku, Kajigaya 1-3-1, Kawasaki, Kanagawa 2120015, Japan
关键词
Rheumatoid arthritis; Renal manifestation; AA-Amyloidosis; IgA nephropathy; Membranous nephropathy; Nephrosclerosis; Disease-modifying antirheumatic drugs (DMARDs); Biologic agent;
D O I
10.1007/s10157-021-02160-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and purpose We examined whether advances in treatment strategies from older disease-modifying antirheumatic drugs (DMARDs) to new biologic agents and methotrexate improved renal complications and outcome in patients with rheumatoid arthritis (RA). Methods We reviewed records of 156 patients with RA who underwent kidney biopsy at our institute between January 1990 and December 2019. All patients were assigned to one of three periods: period 1, 1990-1999 (n = 48); period 2, 2000-2009(n = 57); period 3, 2010-2019 (n = 51). Results Membranous nephropathy, nephrosclerosis, AA-amyloidosis, and IgA nephropathy were the four major renal manifestations of RA. AA-amyloidosis was diagnosed by kidney biopsy in 21 patients: period 1, 7 patients (15%); period 2, 10 patients (18%); and period 3, 4 patients (8%). The 4 patients in period 3 were in the years 2010-2014, and no new case of AA-amyloidosis was recorded from 2015 to 2019. In all 21 of the patients with AA-amyloidosis, neither a biologic agent nor methotrexate was administered. Fifteen of the 21 patients required dialysis, and 13 died in periods 1-3 because of amyloid-related cardiac dysfunction less than 2 years after the initiation of dialysis. Two of them are doing well using biologic agent despite dialysis. The remaining three patients who received a biologic agent or methotrexate does not progress to end-stage renal failure. In addition, the other renal complications showing progression to dialysis also decreased over time. Conclusion Advances in treatment strategies have improved renal outcome and reduced mortality in patients with RA.
引用
收藏
页码:341 / 349
页数:9
相关论文
共 14 条
[1]   Tocilizumab preserves renal function in rheumatoid arthritis with AA amyloidosis and end-stage kidney disease: Two case reports [J].
Fukuda, Makoto ;
Sawa, Naoki ;
Hoshino, Junichi ;
Ohashi, Kenichi ;
Motoaki, Miyazono ;
Ubara, Yoshifumi .
CLINICAL NEPHROLOGY, 2021, 95 (01) :54-61
[2]   RENAL BIOPSY FINDINGS AND CLINICOPATHOLOGICAL CORRELATIONS IN RHEUMATOID-ARTHRITIS [J].
HELIN, HJ ;
KORPELA, MM ;
MUSTONEN, JT ;
PASTERNACK, AI .
ARTHRITIS AND RHEUMATISM, 1995, 38 (02) :242-247
[3]   Membranoproliferative glomerulonephritis and circulating cryoglobulins [J].
Hiramatsu, Rikako ;
Hoshino, Junichi ;
Suwabe, Tatsuya ;
Sumida, Keiichi ;
Hasegawa, Eiko ;
Yamanouchi, Masayuki ;
Hayami, Noriko ;
Sawa, Naoki ;
Takaichi, Kenmei ;
Ohashi, Kenichi ;
Fujii, Takashi ;
Ubara, Yoshifumi .
CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2014, 18 (01) :88-94
[4]   Outcome and treatment of bucillamine-induced nephropathy [J].
Hoshino, Junichi ;
Ubara, Yoshifumi ;
Hara, Shigeo ;
Suwabe, Tatsuya ;
Sawa, Naoki ;
Tagami, Tetsuo ;
Katori, Hideyuki ;
Takemoto, Fumi ;
Hara, Shigeko ;
Takaichi, Kenmei .
NEPHRON CLINICAL PRACTICE, 2006, 104 (01) :C15-C19
[5]   Long term administration of tocilizumab improves renal amyloid A (AA) amyloidosis deposition in Familial Mediterranean fever [J].
Inui, Keita ;
Sawa, Naoki ;
Suwabe, Tatsuya ;
Mizuno, Hiroki ;
Yamanouchi, Masayuki ;
Hiramatsu, Rikako ;
Hayami, Noriko ;
Hoshino, Junichi ;
Kinowaki, Keiichi ;
Fujii, Takeshi ;
Ohashi, Kenichi ;
Ubara, Yoshifumi .
MODERN RHEUMATOLOGY CASE REPORTS, 2020, 4 (02) :310-311
[6]  
KAPLAN JE, 1990, J ACQ IMMUN DEF SYND, V3, P1096
[7]   Treatment with Biologic Agents Improves the Prognosis of Patients with Rheumatoid Arthritis and Amyloidosis [J].
Kuroda, Takeshi ;
Tanabe, Naohito ;
Kobayashi, Daisuke ;
Sato, Hiroe ;
Wada, Yoko ;
Murakami, Shuichi ;
Saeki, Takako ;
Nakano, Masaaki ;
Narita, Ichiei .
JOURNAL OF RHEUMATOLOGY, 2012, 39 (07) :1348-1354
[8]   Revised Equations for Estimated GFR From Serum Creatinine in Japan [J].
Matsuo, Seiichi ;
Imai, Enyu ;
Horio, Masaru ;
Yasuda, Yoshinari ;
Tomita, Kimio ;
Nitta, Kosaku ;
Yamagata, Kunihiro ;
Tomino, Yasuhiko ;
Yokoyama, Hitoshi ;
Hishida, Akira .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (06) :982-992
[9]   Bucillamine induces membranous glomerulonephritis [J].
Nagahama, K ;
Matsushita, H ;
Hara, M ;
Ubara, Y ;
Hara, S ;
Yamada, A .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (04) :706-712
[10]  
Nakano M, 1998, CLIN NEPHROL, V50, P154